Protein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies (PCSK9mab) in Clinical Practice at Secondary Care – Real World Multicentre Experience

Background and Aims Protein convertase subtilisin/Kexin type 9 monoclonal antibodies (PCSK9mab) are a novel addition to the therapeutic options for managing hyperlipidemia. Various guidelines have advocated the addition of these agents if the target low-density lipoprotein-cholesterol ( LDL-C) is no...

Descripción completa

Detalles Bibliográficos
Autores principales: Bashir, Bilal, Haslam, Shonagh, Ahmad, Shaheer, Elnaggar, Mohamed N, Allcock, Rebecca, Ali, Sadaf, Kyi, Nyan M, Salazar, Lorelei, Gbegbaje, Angela, Banerjee, Moulinath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881602/
https://www.ncbi.nlm.nih.gov/pubmed/36721583
http://dx.doi.org/10.7759/cureus.33044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881602/
https://www.ncbi.nlm.nih.gov/pubmed/36721583
http://dx.doi.org/10.7759/cureus.33044

Ejemplares similares